Clinical Trial ID: NCT03486873
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies ThatInclude Pembrolizumab
Status
Open
Conditions
Other
Phases
3
Age Group
Adult
Main Investiagtor
Vu, John
Practice
Head/Neck
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT03486873
Secondary Trial ID Number
MK3475-587-05
Keywords
Treatment